Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025

Received overwhelming shareholder support in favour of take-private transaction with Aditxt

Advanced key pipeline programs, engaged regulatory authorities on ATI-1801 and preparing ATI-1701 for an Investigational New Drug submission

Read more at globenewswire.com